Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

Fineline Cube Jul 29, 2026
Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026
Policy / Regulatory

China’s CDE Tightens Drug Review Standards with New “No Supplemental Data” Rule for Major Deficiencies

Fineline Cube Jul 29, 2026
Company Drug

Guangzhou Innogen’s Ultra-Long-Acting GLP-1 Agonist Efsubaglutide Alfa Advances to Adolescent Obesity Phase Ib Trial Following NMPA Approval for Diabetes

Fineline Cube Jul 29, 2026
Company Drug

Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients

Fineline Cube Jul 29, 2026
Company Drug

Ipsen’s Bylvay Receives NMPA Clearance for Treating Itching in PFIC Patients in China

Fineline Cube Dec 5, 2024

France-based Ipsen (EPA: IPN) has announced that it has received marketing clearance from the National...

Company Drug

Tasly Pharma Receives NMPA Approval for Generic Lioresal (Baclofen) Oral Solution

Fineline Cube Dec 5, 2024

China-based Tasly Pharma Co., Ltd (SHA: 600535) has announced that it has received marketing approval...

Company Drug

Humanwell Healthcare’s Recombinant Plasmid Hepatocyte Growth Factor Injection Accepted for NMPA Review

Fineline Cube Dec 5, 2024

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that the National Medical Products...

Company Drug

Haisco Pharmaceutical’s HSK46575 Receives NMPA Approval for Prostate Cancer Clinical Trial

Fineline Cube Dec 5, 2024

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced the receipt of clinical trial...

Company Drug

Sichuan Kelun-Biotech’s SKB500 Receives NMPA Clinical Clearance for Solid Tumor Treatment

Fineline Cube Dec 5, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd, (HKG: 6990), a leading biopharmaceutical company based in China, has...

Company Drug

Cinclus Pharma’s Linaprazan for GERD Receives NMPA Marketing Approval

Fineline Cube Dec 5, 2024

Sweden-based Cinclus Pharma has announced that it has received marketing approval from the National Medical...

Company

CSPC Pharmaceutical’s CRB-701 Earns FDA Fast Track Designation for Cervical Cancer Treatment

Fineline Cube Dec 5, 2024

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has announced that it has received Fast...

Company Medical Device

Sisram Medical’s Alma Harmony and Alma Hybrid Receive EU Medical Device Certification

Fineline Cube Dec 5, 2024

Sisram Medical Ltd (HKG: 1696), an Israel-based company and part of the Fosun Pharmaceutical Group...

Company Drug

Shanghai Henlius Biotech’s HLX11 Biosimilar Accepted for Review by China’s CDE

Fineline Cube Dec 5, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a leading biopharmaceutical company based in China, has announced...

Company Deals

Wuhan Kaideweisi Biotechnology Secures Series B Funding for Gynecologic Oncology Expansion

Fineline Cube Dec 5, 2024

Wuhan Kaideweisi Biotechnology Co., Ltd, a specialist in gynecologic oncology in China, has reportedly raised...

Company Drug

Shanghai Henlius Biotech’s HLX22 Receives NMPA Approval for Phase II HER2-Targeted Study

Fineline Cube Dec 5, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...

Company Deals

Jiangsu Recbio Technology Secures Private Placement with Yangtze River Pharmaceutical for Vaccine Development

Fineline Cube Dec 5, 2024

China-based Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has successfully placed 142 million shares through...

Company Deals

Hangzhou Chance Pharmaceuticals Partners with Yiling Pharmaceutical for Inhalation Powder Development

Fineline Cube Dec 5, 2024

China’s Hangzhou Chance Pharmaceuticals Co., Ltd., a specialist in lung drug delivery, has entered into...

Company Deals

GRIT Biotechnology and Vitalgen BioPharma Partner on CRISPR-AaCas12bMAX Cell Therapies

Fineline Cube Dec 5, 2024

China-based cell therapy specialists GRIT Biotechnology and Shanghai Vitalgen BioPharma Co., Ltd have entered into...

Company Deals

YiChang HEC ChangJiang Pharmaceutical and DP Technology Deepen Partnership with AI Focus

Fineline Cube Dec 5, 2024

China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced a comprehensive partnership with...

Company Deals

Mabwell Bioscience Enters Licensing Agreement for Biosimilar Denosumab in Peru

Fineline Cube Dec 5, 2024

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a licensing agreement with its...

Company Deals

Analytical BioSciences Sells Global Rights to Pre-Clinical Anti-Tumor Drugs to Gilead

Fineline Cube Dec 4, 2024

Sino-US firm Analytical BioSciences Limited has entered into an asset purchase agreement with Gilead (NASDAQ:...

Company Deals

CanSino Biologics Partners with Etana for Inhaled Tuberculosis Vaccine Development

Fineline Cube Dec 4, 2024

China-based CanSino Biologics (SHA: 688185, HKG: 6185) has entered into a strategic partnership with Indonesia-based...

Company Deals

Zhida Pharma Secures Licensing Deal for Vivesto AB’s Apealea in China

Fineline Cube Dec 4, 2024

Zhejiang-based Zhida Pharma has announced a licensing deal with Sweden-headquartered Vivesto AB (STO: VIVE), securing...

Company Deals

Guangzhou Innogen Pharmaceutical Files for IPO on Hong Kong Stock Exchange

Fineline Cube Dec 4, 2024

Guangzhou Innogen Pharmaceutical Group Co., Ltd., a China-based pharmaceutical company, has made an initial public...

Posts pagination

1 … 288 289 290 … 701

Recent updates

  • Guangzhou Innogen’s Ultra-Long-Acting GLP-1 Agonist Efsubaglutide Alfa Advances to Adolescent Obesity Phase Ib Trial Following NMPA Approval for Diabetes
  • GSK Commits £400 Million to Establish Major Cambridge R&D Center, Consolidating UK Research Operations
  • Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients
  • Hansoh Pharmaceutical’s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership
  • Shionogi Launches XOCOVA (Ensitrelvir) in US for COVID-19 Post-Exposure Prophylaxis Following 67% Risk Reduction in Global Trial
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Guangzhou Innogen’s Ultra-Long-Acting GLP-1 Agonist Efsubaglutide Alfa Advances to Adolescent Obesity Phase Ib Trial Following NMPA Approval for Diabetes

Company

GSK Commits £400 Million to Establish Major Cambridge R&D Center, Consolidating UK Research Operations

Company Drug

Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.